# Phathom Pharmaceuticals (PHAT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PHAT
## Company Profile
- Ticker: PHAT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 9.17 USD
- Market cap: 769644946.45 USD
- Last updated: 2026-08-12
## Business Overview
### Gastrointestinal Medicines
Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker.
### VOQUEZNA Franchise
VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux disease, healing and maintenance of erosive GERD, and as dual- or triple-drug packs for Helicobacter pylori infection. Its mechanism provides rapid and durable acid suppression distinct from proton-pump inhibitors.
### Eosinophilic Esophagitis Development
The Phase 2 pHalcon-EoE-201 trial is evaluating VOQUEZNA in eosinophilic esophagitis. This program tests whether strong acid suppression can benefit a chronic inflammatory esophageal disease and extend the franchise into another specialist-treated indication.
## Why The Stock Is Moving

As of Aug 12, 2026, PHAT closed up 7.76% at $9.17. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from the Phase 2 pHalcon-EoE-201 trial expected in late fourth-quarter 2026 or early first-quarter 2027.

## Drug Assets

- VOQUEZNA

## Recent News
- 2026-07-30 10:59 EST — [Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provid-09026018) — Source: Phathom Pharmaceuticals
- 2026-07-20 12:00 EST — [Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-report-second-quarter-2026-financial-results-and-prov-7a7f699d) — Source: Phathom Pharmaceuticals
- 2026-06-23 11:59 EST — [Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-schedule-in-phase--929df80d) — Source: Phathom Pharmaceuticals
- 2026-05-22 12:00 EST — [Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-09df65d6) — Source: Phathom Pharmaceuticals
- 2026-05-20 12:00 EST — [Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-highlights-breadth-of-independent-vonoprazan-research-at-digestive-disease-week-2026-annual-meeting) — Source: Phathom Pharmaceuticals